Key Highlights

  • Pre-market market data put SELLAS Life Sciences at USD 9.25 on Friday, November 13, 2026, a 15.19% advance, and searches found no company announcement dated November 11 to 13.
  • The Phase 3 REGAL study hit its prespecified 80th overall survival event on October 28, 2026, which starts the final analysis, and a published report pegged that day's share decline at 18%.
  • Early topline numbers for galinpepimut-S, a WT1-directed immune therapy tested in acute myeloid leukemia patients in second remission, should arrive this quarter, but no particular day has been set.
  • Cash and equivalents stood at USD 138.3 million on June 30, 2026, and market data show about 201.95 million shares, which implies a Market Value near USD 1.87 billion at USD 9.25 (calculated).

Rebound Follows the October 28 Sell-Off

SELLAS Life Sciences (NASDAQ:SLS) traded at USD 9.25 before regular activity on Friday, November 13, 2026, a 15.19% rise over an implied prior price near USD 8.03 (calculated). No release, filing or analyst note dated November 11 to 13 surfaced in searches. On October 28 the company announced that REGAL had reached its 80th event, the trigger for database lock, unblinding and analysis of overall survival, the primary endpoint. Shares slid that day, with one report citing 18% and another a finish of USD 10.38, down 14.71%. A bounce can follow a drop even without fresh news, and the USD 9.25 quote remains below the USD 10.38 level reached after the milestone news.

What REGAL Tests and When Its Data Arrive

REGAL is a randomized study intended for registration, testing galinpepimut-S as maintenance treatment for adults with acute myeloid leukemia in second complete remission. The therapy is licensed from Memorial Sloan Kettering Cancer Center. Because the study is event-driven, the 80th death fixed the timing of the analysis. The company aims to publish early topline results before the quarter ends on December 31, 2026, and separately plans to show SLS009 combination findings in high-risk AML at the 2026 American Society of Hematology gathering. Published coverage gives December 14 for that presentation. SLS009, a CDK9 inhibitor, is a second program, though near-term value rests mostly on galinpepimut-S.

Binary Outcome, Cash Runway and Financing Odds

For SELLAS Life Sciences (NASDAQ:SLS), a single readout could move the valuation sharply either way, and the decline after the milestone showed holders did not treat it as a sure win. Against USD 138.3 million of cash as of June 30, market data show a net loss near USD 32.5 million, but the window that loss covers is uncertain, which makes any runway estimate unreliable. Positive results could prompt a Capital raise, while negative results could threaten the program. The 52-week range runs from USD 1.39 to USD 15.88, and pre-market moves can reverse. Recent coverage put the year-to-date gain near 128% as of November 10, which suggests expectations were already high heading into the readout.

Where Things Stand

No news could be tied to the 15.19% pre-market advance in SELLAS Life Sciences (NASDAQ:SLS), which reads more like a recovery after the October 28 fall plus positioning ahead of the REGAL readout. The USD 9.25 figure covers pre-market activity only. The picture is balanced: the milestone has been reached, but the results are not yet known. Upcoming checkpoints are the topline release expected this quarter, the December SLS009 presentation, the third-quarter filing and any raise that follows the readout.